	US 12,326,451 B2
	Severe acute respiratory syndrome (SARS)—associated coronavirus diagnostics
Sylvie Van Der Werf, Paris (FR); Nicolas Escriou, Paris (FR); Caroline Demeret, Paris (FR); Stéphane Petres, Paris (FR); Pierre Lafaye, Paris (FR); and Jacques Bellalou, Paris (FR)
Assigned to INSTITUT PASTEUR, Paris (FR)
Filed by INSTITUT PASTEUR, Paris (FR)
Filed on Jul. 23, 2020, as Appl. No. 16/936,752.
Claims priority of provisional application 63/003,855, filed on Apr. 1, 2020.
Prior Publication US 2021/0311054 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/569 (2006.01); C07K 14/005 (2006.01); C12N 15/70 (2006.01)

CPC G01N 33/56983 (2013.01) [C07K 14/005 (2013.01); C12N 15/70 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20031 (2013.01); G01N 2333/165 (2013.01); G01N 2800/26 (2013.01)]

18 Claims

1. A kit for detection of a severe acute respiratory syndrome (SARS)-associated coronavirus infection in a biological sample comprising:

a severe acute respiratory syndrome-associated coronavirus 2 nucleocapsid protein (SARS-CoV-2 N protein) fused to a N-terminally located poly-histidine tag containing 6 histidines, made by a process comprising expressing and purifying said SARS-CoV-2 N protein fused to a N-terminally located poly-histidine tag containing 6 histidines from Escherichia coli (E. coli) strain BL21 (DE3) pDIA17 transformed with recombinant plasmid pETM11/N-nCov E. coli 3-(His)_6-Nteror pETM11/N-nCov E. coli 4-(His)_6-Nterdeposited at the Collection Nationale de Cultures de Microorganismes (CNCM) at the Institut Pasteur, 25, Rue du Docteur Roux, 75724 Paris, France, on May 11, 2020, under the deposit numbers CNCM 1-5510 and CNCM 1-5511, respectively; and

a severe acute respiratory syndrome-associated coronavirus 2 spike protein (SARS-CoV-2 S protein).